More on FDA’s Guidance for 503A Compounding of COVID-19 Meds
Following our previous posts on FDA’s guidance released this week, Dr. David Hussong discusses the terms stipulated by the temporary policy which allows 503A pharmacies to compound certain drugs for COVID-19 without patient-specific prescriptions.
Watch this episode of Eagle TV to hear more! Have a question for our experts? Visit our COVID-19 resource page and access our fact check form to get science-based answers from our team.
Subscribe to our YouTube Channel to get alerts when we post videos
Eagle is an FDA and DEA registered, A2LA ISO 17025 accredited laboratory providing analytical and microbiological testing services along with expert consulting services to 503A compounding pharmacies, 503B outsourcing facilities, and pharmaceutical companies.
Latest posts by Eagle Analytical (see all)
- EAGLE Seminar Conference 2021|🦅EVENT NOTICE - September 9, 2021
- Happy Labor Day Everyone – Eagle will be closed on 09/06 - September 1, 2021
- Environmental Monitoring Analyses: Early Warning Opportunities for Sterile Compounders - July 23, 2021
